Amgen Inc. is starting to reach key value-inflection points in its early-stage cancer drug pipeline as it attempts to develop a portfolio of innovative, differentiated therapies that will be effective on their own and build on the promise of immuno-oncology agents, such as PD-1 inhibitors.
The company has a well-established portfolio of blockbuster supportive care therapies, including the anemia treatment Epogen (epoetin alfa), neutropenia therapies...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

